Trends in systemic lupus erythematosus mortality in Spain from 1981 to 2010

Ruiz, Elena; Ramalle-Gómara, Enrique; Elena, A. Villacorte; Quiñones, Carmen; Alonso-Ferreira, Verónica; Paz, Manuel Posada de la

doi:10.1177/0961203313517015

Cited by 23 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar trends have been noted in Spain using ICD-9-CM codes to identify cases; however, only males with lupus were noted to have decreased mortality. [16] In Taiwan, ICD-9-CM codes have been used to identify cases of lupus and clarify morbidity associated with ICD-9-CM diagnosis code for lupus complications—these include risk of heart failure, hypertension, osteoporosis, cataracts, glaucoma, dyslipidemia, seizures, encephalopathy, and malignant changes—compared to non-lupus populations. [17]…”

Section: Discussionmentioning

confidence: 99%

Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011

et al. 2015

View full text Add to dashboard Cite

BackgroundSystemic lupus erythematosus (SLE or lupus) is an autoimmune multisystem disease. While a complete understanding of lupus’ origins, mechanisms, and progression is not yet available, a number of studies have demonstrated correlations between disease prevalence and severity, gender, and race. There have been few population based studies in the United StatesObjectivesTo assess temporal changes in demographics and hospital mortality of patients with lupus in Washington State from 2003 to 2011Study DesignThis study used data from the Healthcare Cost and Utilization Project (HCUP), a patient information database, and data from the Washington State census to study a group of patients in the state. Lupus hospitalizations were defined as any hospitalization with an ICD-9-CM diagnosis code for systemic lupus erythematosus. Regression analysis was used to assess the effect of calendar time on demographics and hospital outcomes.ResultsThere were a total of 18,905 patients in this study with a diagnostic code for lupus. The mean age of the group was 51.5 years (95% CI: 50.6-52.3) in 2003 and 51.3 years (95% CI: 50.6-52.0) in 2011. The population was 88.6% female. Blacks were 2.8 times more likely to have a lupus hospitalization than whites when compared to the Washington population. While hospital mortality decreased during this eight year period (3.12% in 2003 to 1.28% in 2011, p=0.001) hospital length of stay remained statistically unchanged at an average of 4.9 days during that eight year period. We found a significant decrease in annual hospital mortality over the study period [odds ratio(OR): 0.92 per year, 95% CI 0.88-0.96, P<0.001]. Hospital mortality was higher in males (2.6% male death to 1.8% female death)ConclusionsIn this large group of hospitalized lupus patients in Washington, hospital length of stay remained relatively stable over time but hospital mortality decreased by over 50% over the eight year study period.

show abstract

Section: Discussionmentioning

confidence: 99%

Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In a study done in Spain, the overall age-standardised mortality rate for systemic lupus erythematosus (SLE) increased during 1981 -1999 and stabilised during 2000 -2010. [1] The mean age at death increased with time, from 42 years in 1981 to 61 years in 2010. [1] Similar mortality trends have been observed in patients with rheumatoid arthritis (RA), even though mortality still remains higher in RA patients compared with the general population.…”

mentioning

confidence: 98%

“…[1] The mean age at death increased with time, from 42 years in 1981 to 61 years in 2010. [1] Similar mortality trends have been observed in patients with rheumatoid arthritis (RA), even though mortality still remains higher in RA patients compared with the general population. [2] The overall SLE survival rates have increased significantly between the 1950s and 2000s, from 74.8% to 94.8% and 63.2% to 91.4% for the overall 5-year and 10-year survival, respectively.…”

mentioning

confidence: 98%

Musculoskeletal disorders – disease burden and challenges in the developing world

Gcelu

Kalla

2015

S Afr Med J

View full text Add to dashboard Cite

“…In the past decades, the mortality rates have decreased considerably, and SLE as a chronic disease now has a 5-year survival rate of >90%. 1 2 Treatment with immunosuppressive drugs can help to keep organ involvement manageable and allow many patients to achieve remission or at least maintain a low disease activity. 3 …”

Section: Introductionmentioning

confidence: 99%

Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo evaluate trends in the referral, treatment and outcome of patients with systemic lupus erythematosus (SLE) in Germany over two decades.MethodsFrom 1993 to 2012, ∼1200 patients with SLE were recorded annually in the national database of the German Collaborative Arthritis Centres. Treatment patterns, healthcare use and outcomes, such as disease activity, function and work participation, were evaluated over time. Furthermore, two distinct cohorts of patients (enrolment 1994–1998, n=467; and 2004–2008, n=376) observed over 5 years were assessed for changes in outcomes.ResultsThe mean disease duration at the first visit to a rheumatologist decreased from 2.6 (1994) to 1.5 (2012) years. Glucocorticoids (69%), antimalarials (56%), azathioprine (22%), non-steroidal anti-inflammatory drugs (23%) and mycophenolate mofetil (15%) were the most frequently used treatments in 2012. A significant increase was observed in the use of antimalarials and mycophenolate mofetil. The use of glucocorticoids at >7.5 mg/day decreased from 27% (1994) to 10% (2012). The average length of sick leave taken due to SLE declined from 9 weeks (1997) to 6 weeks (2012). When comparing the two longitudinal cohorts, in the cohort from the 2000s, the intraindividual decline of disease activity was significantly stronger (p<0.001), and fewer patients retired early (36% vs 46%).ConclusionsThe disease activity and resource use declined considerably over the observation period, and more patients remained in the labour force. Earlier treatment onset, faster modification of the treatment regimen and more intensive use of anti-inflammatory therapy may account for the improved outcomes in patients with SLE across the years.

show abstract

Trends in systemic lupus erythematosus mortality in Spain from 1981 to 2010

Abstract: In conclusion, a slight decrease in SLE mortality has been observed in Spain over the last decade and future studies would be needed to explain the factors contributing to the improvement in the mortality rates.

Cited by 23 publications

References 12 publications

Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011

Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011

Musculoskeletal disorders – disease burden and challenges in the developing world

Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s

Contact Info

Product

Resources

About